-- Oncology -- Hybrid imaging solutions such as the Biograph(TM) family of PET-CT systems and the Symbia(R) family of SPECT-CT scanners produce true clarity with unmatched image quality and resolution, offering enhanced diagnostic confidence from initial diagnosis to therapy planning, staging and follow-up. Siemens' new TruePoint(TM) PET-CT platform will provide dramatic improvements in the clinical capabilities of PET-CT. In addition, the company's hybrid imaging systems are enhanced by software suites such as the syngo(R) MultiModality Workplace, which offers intuitive post processing and advanced visualization. syngo TrueD(TM), for example, is a tool that enables physicians to quickly co-register and compare patient scans from different points in time, such as pre- and post- therapy.

-- Cardiology -- True efficiency and integration are achieved with Siemens' cardiology solutions, including c.cam(TM), e.cam(R), Symbia SPECT, Symbia SPECT-CT, and Biograph PET-CT systems. Siemens' molecular imaging solutions provide cardiologists with functional information such as wall motion, myocardial perfusion, and in some cases plaque characterization, as well as morphological information, such as the presence of coronary calcifications and detailed cardiac anatomy. New workflow enhancements to the Symbia line of hybrid imagers include automatic and integrated collimator changing options, as well as an automatic quality control option that automates all daily, weekly and monthly quality control needs of the system. Siemens Biograph 64 with the new TruePoint PET-CT technology package performs high-resolution CT angiography and myocardial perfusion and viability in a single exam. These technologies, combined with advanced visualization tools such as syngo CardioFusion, optimize the clinical cardiac workflow and enable enhanced diagnostic capabilities.


-- Neurology -- In addition to hybrid technologies, which are gaining momentum in the neurological environment, sophisticated computer-aided brain function analysis tools like syngo Scenium facilitate neurological evaluation by enabling automatic correlation of a patient study with an average brain for assessment of abnormalities. These software advancements will benefit physicians by enabling quick, precise diagnoses, and reproducible results. Other advancements include imaging biomarkers that will help physicians detect both beta-amyloid plaques and neuronal tangles to predict the onset of dementia and neurological disorders - often before symptoms appear. This will not only facilitate earlier treatment, but also the development of better drugs that effectively manage the progression of disease.

More Industry Headlines